Literature DB >> 1130420

Central nervous system disease in systemic lupus erythematosus. Therapy and prognosis.

J S Sergent, M D Lockshin, M S Klempner, B A Lipsky.   

Abstract

The effect of corticosteroid therapy in 28 patients with 52 episodes of neuropyciatric disease in systemic lupus erythematosus (SLE) was elevated. Categories of organic central nervous system disease were seizures (eight patients), organic brain syndromes (nine patients), aseptic meningitis (four patients) and a variety of focal neurologic findings (seven patinets). Fourteen pateints had 15 episodes of functional psychosis without other evidence of neurologic disease. Although there was a general correlation between clinical and serologic evidnce of active SLE and the development of organic neurolgic disease, there was no evidence that therapy with very large doses of corticosteroids was beneficial. Of the deaths in this series, two were due to probable active SLE involving the central nervous system wheras five were attributable to complications of therapy. The long-term morbidity, likewise, was high in the patients who recieved large doses of corticosteroids. In all, 12 patients had major complications of corticosteroid therapy. Functional psychosis was usually preciptated by corticsoteroid therapy and respond to a reduction in steroid dosage and administration of psychotropic drugs.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1130420     DOI: 10.1016/0002-9343(75)90500-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  27 in total

Review 1.  Adverse neurologic effects of glucocorticosteroids.

Authors:  D Lacomis; M A Samuels
Journal:  J Gen Intern Med       Date:  1991 Jul-Aug       Impact factor: 5.128

2.  Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case-control study from a single center.

Authors:  Melissa Padovan; Gabriella Castellino; Alessandra Bortoluzzi; Luisa Caniatti; Francesco Trotta; Marcello Govoni
Journal:  Rheumatol Int       Date:  2010-07-31       Impact factor: 2.631

3.  Jaw Dystonia and Reversible Basal Ganglia Changes as an Initial Presentation of Systemic Lupus Erythematosus.

Authors:  Meghan Romba; Yujie Wang; Shu-Ching Hu; Sandeep Khot
Journal:  Neurohospitalist       Date:  2017-03-10

4.  Clinical neurophysiology in the assessment of neurological symptoms in systemic lupus erythematosus.

Authors:  A B Mongey; D Glynn; M Hutchinson; B Bresnihan
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

Review 5.  Systemic lupus erythematosus: treatment and prognosis.

Authors:  G R Hughes
Journal:  Br Med J       Date:  1979-10-27

Review 6.  Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus.

Authors:  Samir D Bhangle; Neil Kramer; Elliot D Rosenstein
Journal:  Rheumatol Int       Date:  2013-04-16       Impact factor: 2.631

7.  Prolonged complete remission in previously severe SLE.

Authors:  E C Tozman; M B Urowitz; D D Gladman
Journal:  Ann Rheum Dis       Date:  1982-02       Impact factor: 19.103

8.  Brain single-photon emission tomography with 99mTc-HMPAO in neuropsychiatric systemic lupus erythematosus: relations with EEG and MRI findings and clinical manifestations.

Authors:  P Colamussi; M Giganti; C Cittanti; L Dovigo; F Trotta; M R Tola; R Tamarozzi; G Lucignani; A Piffanelli
Journal:  Eur J Nucl Med       Date:  1995-01

9.  Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus.

Authors:  Mohamed O Olfat; Sulaiman M Al-Mayouf; Mohamed A Muzaffer
Journal:  Clin Rheumatol       Date:  2004-07-23       Impact factor: 2.980

10.  Anorexia nervosa in a patient with systemic lupus erythematosus.

Authors:  P Bambery; S Malhotra; U Kaur; R Chadda; S D Deodhar
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.